vs
Side-by-side financial comparison of Legacy Housing Corp (LEGH) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
Legacy Housing Corp is the larger business by last-quarter revenue ($25.5M vs $23.0M, roughly 1.1× Intellia Therapeutics, Inc.). Legacy Housing Corp runs the higher net margin — 32.2% vs -416.2%, a 448.3% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs -30.6%). Legacy Housing Corp produced more free cash flow last quarter ($15.7M vs $-69.4M). Over the past eight quarters, Legacy Housing Corp's revenue compounded faster (-9.1% CAGR vs -10.8%).
Legacy Housing Corp is a prominent U.S.-based manufacturer of affordable manufactured homes, tiny homes, and accessory dwelling units. It mainly caters to low- and middle-income consumers across North America, providing customizable residential solutions, supporting construction materials, and after-sales services for individual and community development clients.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
LEGH vs NTLA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.5M | $23.0M |
| Net Profit | $8.2M | $-95.8M |
| Gross Margin | 26.4% | — |
| Operating Margin | 40.4% | -428.9% |
| Net Margin | 32.2% | -416.2% |
| Revenue YoY | -30.6% | 78.8% |
| Net Profit YoY | -43.5% | 25.7% |
| EPS (diluted) | $0.38 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $25.5M | $23.0M | ||
| Q3 25 | $28.8M | $13.8M | ||
| Q2 25 | $38.4M | $14.2M | ||
| Q1 25 | $24.3M | $16.6M | ||
| Q4 24 | $36.7M | $12.9M | ||
| Q3 24 | $30.2M | $9.1M | ||
| Q2 24 | $31.7M | $7.0M | ||
| Q1 24 | $30.8M | $28.9M |
| Q4 25 | $8.2M | $-95.8M | ||
| Q3 25 | $8.6M | $-101.3M | ||
| Q2 25 | $14.7M | $-101.3M | ||
| Q1 25 | $10.3M | $-114.3M | ||
| Q4 24 | $14.5M | $-128.9M | ||
| Q3 24 | $15.8M | $-135.7M | ||
| Q2 24 | $16.2M | $-147.0M | ||
| Q1 24 | $15.1M | $-107.4M |
| Q4 25 | 26.4% | — | ||
| Q3 25 | 20.2% | — | ||
| Q2 25 | 32.4% | — | ||
| Q1 25 | 29.2% | — | ||
| Q4 24 | 27.3% | — | ||
| Q3 24 | 29.2% | — | ||
| Q2 24 | 31.9% | — | ||
| Q1 24 | 33.6% | — |
| Q4 25 | 40.4% | -428.9% | ||
| Q3 25 | 33.7% | -808.9% | ||
| Q2 25 | 43.8% | -772.2% | ||
| Q1 25 | 47.7% | -726.6% | ||
| Q4 24 | 42.3% | -1059.9% | ||
| Q3 24 | 50.8% | -1589.0% | ||
| Q2 24 | 50.6% | -1998.6% | ||
| Q1 24 | 54.3% | -394.0% |
| Q4 25 | 32.2% | -416.2% | ||
| Q3 25 | 30.0% | -735.2% | ||
| Q2 25 | 38.3% | -710.8% | ||
| Q1 25 | 42.3% | -687.6% | ||
| Q4 24 | 39.5% | -1001.2% | ||
| Q3 24 | 52.4% | -1489.5% | ||
| Q2 24 | 51.1% | -2112.6% | ||
| Q1 24 | 49.1% | -371.3% |
| Q4 25 | $0.38 | $-0.81 | ||
| Q3 25 | $0.35 | $-0.92 | ||
| Q2 25 | $0.60 | $-0.98 | ||
| Q1 25 | $0.41 | $-1.10 | ||
| Q4 24 | $0.59 | $-1.27 | ||
| Q3 24 | $0.64 | $-1.34 | ||
| Q2 24 | $0.65 | $-1.52 | ||
| Q1 24 | $0.60 | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $449.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $528.6M | $671.4M |
| Total Assets | $580.3M | $842.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $449.9M | ||
| Q3 25 | $13.6M | $511.0M | ||
| Q2 25 | $2.6M | $459.7M | ||
| Q1 25 | $3.4M | $503.7M | ||
| Q4 24 | $1.1M | $601.5M | ||
| Q3 24 | $570.0K | $658.1M | ||
| Q2 24 | $60.0K | $691.1M | ||
| Q1 24 | $621.0K | $791.3M |
| Q4 25 | $528.6M | $671.4M | ||
| Q3 25 | $521.6M | $748.4M | ||
| Q2 25 | $512.8M | $715.3M | ||
| Q1 25 | $503.7M | $779.9M | ||
| Q4 24 | $494.0M | $872.0M | ||
| Q3 24 | $479.3M | $962.6M | ||
| Q2 24 | $463.2M | $971.1M | ||
| Q1 24 | $450.4M | $1.0B |
| Q4 25 | $580.3M | $842.1M | ||
| Q3 25 | $557.9M | $925.3M | ||
| Q2 25 | $552.0M | $898.9M | ||
| Q1 25 | $544.6M | $986.2M | ||
| Q4 24 | $534.2M | $1.2B | ||
| Q3 24 | $521.4M | $1.2B | ||
| Q2 24 | $514.9M | $1.2B | ||
| Q1 24 | $510.0M | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $19.0M | $-69.3M |
| Free Cash FlowOCF − Capex | $15.7M | $-69.4M |
| FCF MarginFCF / Revenue | 61.6% | -301.6% |
| Capex IntensityCapex / Revenue | 13.1% | 0.5% |
| Cash ConversionOCF / Net Profit | 2.32× | — |
| TTM Free Cash FlowTrailing 4 quarters | $28.2M | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.0M | $-69.3M | ||
| Q3 25 | $7.2M | $-76.9M | ||
| Q2 25 | $6.1M | $-99.6M | ||
| Q1 25 | $4.9M | $-148.9M | ||
| Q4 24 | $7.9M | $-85.2M | ||
| Q3 24 | $13.8M | $-84.8M | ||
| Q2 24 | $3.5M | $-58.2M | ||
| Q1 24 | $10.8M | $-120.7M |
| Q4 25 | $15.7M | $-69.4M | ||
| Q3 25 | $5.1M | $-76.9M | ||
| Q2 25 | $3.7M | $-99.9M | ||
| Q1 25 | $3.6M | $-149.7M | ||
| Q4 24 | $6.0M | $-86.2M | ||
| Q3 24 | $9.1M | $-86.1M | ||
| Q2 24 | $1.7M | $-59.2M | ||
| Q1 24 | $9.9M | $-123.2M |
| Q4 25 | 61.6% | -301.6% | ||
| Q3 25 | 17.8% | -558.2% | ||
| Q2 25 | 9.6% | -701.0% | ||
| Q1 25 | 15.0% | -900.1% | ||
| Q4 24 | 16.4% | -669.4% | ||
| Q3 24 | 30.2% | -945.2% | ||
| Q2 24 | 5.4% | -850.9% | ||
| Q1 24 | 32.2% | -425.7% |
| Q4 25 | 13.1% | 0.5% | ||
| Q3 25 | 7.1% | 0.2% | ||
| Q2 25 | 6.2% | 1.7% | ||
| Q1 25 | 5.2% | 4.4% | ||
| Q4 24 | 5.1% | 7.6% | ||
| Q3 24 | 15.6% | 14.0% | ||
| Q2 24 | 5.5% | 14.5% | ||
| Q1 24 | 2.8% | 8.7% |
| Q4 25 | 2.32× | — | ||
| Q3 25 | 0.83× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.48× | — | ||
| Q4 24 | 0.54× | — | ||
| Q3 24 | 0.88× | — | ||
| Q2 24 | 0.21× | — | ||
| Q1 24 | 0.71× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LEGH
| Commercial Sales | $8.6M | 34% |
| Retail Store Sales | $6.0M | 24% |
| Inventory Finance Sales | $5.0M | 20% |
| Direct Sales | $4.4M | 17% |
| Other | $1.5M | 6% |
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
